Avidity biosciences announces upcoming presentations at the 2022 mda clinical & scientific conference

San diego, march 7, 2022 /prnewswire/ -- avidity biosciences, inc. (nasdaq: rna), a biopharmaceutical company committed to delivering a new class of rna therapeutics called antibody oligonucleotide conjugates (aocs™), today announced they will be presenting an oral presentation and multiple poster presentations at the 2022 mda clinical & scientific conference in nashville, tennessee, march 13-16, 2022. oral presentation   march 16, 2022: 9:30 am – 10:45 am ct dux4 sirna optimization for the development of an antibody-oligonucleotide conjugate (aoc™) for the treatment of fshd poster presentations march 13-15, 2022: 6:00 pm – 8:00 pm ct understanding the patients' journey pre- and post-diagnosis of facioscapulohumeral muscular dystrophy (fshd): a real-world retrospective data analysis prevalence of healthcare conditions and services used by patients with myotonic dystrophy pre-and post-diagnosis, a real-world data analysis a phase 1/2 clinical trial evaluating the safety and pharmacokinetics of aoc 1001 in adults with myotonic dystrophy type 1 (dm1): marina study design once available, posters and presentations will be on the publications page of our website at https://www.aviditybiosciences.com.
RNA Ratings Summary
RNA Quant Ranking